Drug
Arv 471
Arv 471: highest development phase Phase 3, developed by Arvinas, Pfizer. 7 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Arvinas, Pfizer
Trials
| Drug | Phase | Indication |
|---|---|---|
| ARV-471 NCT05654623 | Phase 3 | Advanced Breast Cancer |
| ARV-471 NCT05549505 | Phase 2 | Breast Cancer |
| ARV-471 NCT05573555 | Phase 1/2 | Breast Cancer |
| ARV-471 NCT05548127 | Phase 1/2 | Breast Cancer |
| ARV-471 NCT05652660 | Phase 1 | Healthy |
| ARV-471 NCT05673889 | Phase 1 | Healthy |
| ARV-471 NCT05732428 | Phase 1 | Breast Cancer |
Latest
No recent events.
Follow Arv 471 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.